{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:34:33Z","timestamp":1771050873714,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T00:00:00Z","timestamp":1488153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>To the authors' knowledge, the optimal frequency of monitoring after tyrosine kinase inhibitor (TKI) discontinuation in patients with chronic myeloid leukemia (CML) has not been established. Data regarding the discontinuation of second\u2010generation TKIs used in first\u2010line treatment or after the failure of first\u2010line treatment with TKIs are limited. Herein, the authors report real\u2010world experience with \u201creduced frequency\u201d molecular monitoring in patients with CML in all phases who discontinued treatment with imatinib, dasatinib, or bosutinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The records of patients who discontinued TKIs were reviewed. Patients who discontinued TKIs were monitored prospectively on an intended schedule of monthly blood quantitative reverse transcriptase\u2010polymerase chain reaction for <jats:italic>BCR\u2010ABL1<\/jats:italic> for 3 months, quarterly for 12 months, and every 6 months thereafter until loss of major molecular response (MMR). After loss of MMR, the TKI that previously was discontinued was reinitiated.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Between January 2010 and September 2015, a total of 24 patients in chronic (21 patients), accelerated (2 patients), and lymphoid blast (1 patient) phase discontinued imatinib (16 patients), dasatinib (5 patients), or bosutinib (3 patients) used in the front\u2010line treatment or beyond. Blood quantitative reverse transcriptase\u2010polymerase chain reaction for <jats:italic>BCR\u2010ABL1<\/jats:italic> was performed 1.3 \u00b1 0.7 times within the first 3 months (24 patients) and 2.7 \u00b1 1.4 times in the following 12 months (18 patients). With a median follow\u2010up of 36.5 months (range, 3.2\u201067.4 months), the probabilities of treatment\u2010free remission at 1 year and 2 years were 65.7% (95% confidence interval, 55.8%\u201075.6%) and 59.7% (95% confidence interval, 49.1%\u201070.3%), respectively. Loss of MMR was observed in 9 patients at a median of 2.8 months (range, 1.8\u201014.2 months) after discontinuation of TKIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>With the limitations of a small sample size, the results of the current study demonstrate that less frequent monitoring of <jats:italic>BCR\u2010ABL1<\/jats:italic> does not appear to affect outcomes, and that discontinuation of TKIs used as first\u2010line treatment or beyond after resistance or intolerance to first\u2010line treatment appears feasible. <jats:bold><jats:italic>Cancer<\/jats:italic> 2017;123:2482\u201388.<\/jats:bold> \u00a9 <jats:italic>2017 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.30608","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T16:12:46Z","timestamp":1488211966000},"page":"2482-2488","source":"Crossref","is-referenced-by-count":9,"title":["Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?"],"prefix":"10.1002","volume":"123","author":[{"given":"Jee Hyun","family":"Kong","sequence":"first","affiliation":[{"name":"Division of Hematology\u2010Oncology Department of Internal Medicine, Wonju Severance Hospital, Yonsei College of Medicine Wonju Korea"},{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliott F.","family":"Winton","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard T.","family":"Heffner","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengjia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia A.","family":"Langston","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Arellano","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuad","family":"El\u2010Rassi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Jillella","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamsi K.","family":"Kota","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imre","family":"Bod\u00f3","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna Jean","family":"Khoury","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,2,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7146"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23427"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.06.018"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.831092"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.3.691.691"},{"key":"e_1_2_8_9_1","volume-title":"The World Health Organization (WHO) Classification of Tumors of the Hematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-013-0006-3"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.1221"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.02.011"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.056853"},{"key":"e_1_2_8_15_1","unstructured":"ClinicalTrials.gov.The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02269267. Accessed December 12 2016."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.30608","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.30608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:32:02Z","timestamp":1760279522000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,27]]},"references-count":14,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/cncr.30608"],"URL":"https:\/\/doi.org\/10.1002\/cncr.30608","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,27]]}}}